The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
CTC study opens for relapsed Hodgkin lymphoma patients
25 March 2019
The CR UK & UCL Cancer Trials Centre has announced the opening of a UK-based cancer trial called ANIMATE, supported by Bristol-Myers Squibb. 

The study is assessing how effective the use of the drug nivolumab is for patients with Hodgkin lymphoma who have relapsed after their initial treatment and for whom subsequent treatment has not been effective. 

Patients taking part in the study will have been diagnosed with classical Hodgkin lymphoma and have undergone chemotherapy which either did not eliminate their disease, or initially eliminated a disease which has since returned. After completing up to two further courses of chemotherapy, which is known as salvage therapy, eligible patients can take part in the ANIMATE trial, where they will be offered nivolumab in an attempt to eliminate their disease or help control it to allow them to receive a stem cell transplant.

Nivolumab is an anti-PD1 monoclonal antibody that blocks the PD1 protein from forming on the surface of cells. This process normally regulates inflammation as a reaction to foreign bodies, but when the protein forms on cancer cells it can prevent the immune system from destroying them. By disrupting this function with nivolumab, cancer cells are more susceptible to the immune system and less able to repair themselves. 

ANIMATE is now open to recruitment. With the first patient having started trial treatment in January, researchers will require up to 120 patients to take part and, of those, they hope 30 will be eligible to receive treatment with nivolumab. The trial will open in up to 30 hospital sites across the UK and is due to complete recruitment by December 2021.

More details on the trial can be found here.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us